Page last updated: 2024-11-04

temozolomide and Hemorrhagic Diathesis

temozolomide has been researched along with Hemorrhagic Diathesis in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy."7.76Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010)
"Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy."3.76Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kopecký, J1
Priester, P1
Slovácek, L1
Petera, J1
Kopecký, O1
Macingova, Z1

Other Studies

1 other study available for temozolomide and Hemorrhagic Diathesis

ArticleYear
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2010, Volume: 186, Issue:8

    Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea

2010